相关实验视频

Updated: Jun 15, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

[抗体-药物结合剂用于治疗白血病和淋巴瘤-目前的状况,问题和未来的发展]

Naoko Ida¹, Takahiro Yamauchi

¹Dept. of Hematology and Oncology, University of Fukui.

Gan to kagaku ryoho. Cancer & chemotherapy

|August 27, 2024

概括

抗体-药物结合物 (ADCs) 在治疗白血病和淋巴瘤方面具有很高的疗效. 需要进一步的研究,以了解ADC抵抗机制,以改善癌症治疗.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

抗体-药物合物 (ADCs) 通过向抗体进行精确的癌症治疗,提高疗效和降低毒性.
在日本批准用于白血病和淋巴瘤的四种ADC,包括gemtuzumab ozogamicin,brentuximab vedotin,inotuzumab ozogamicin和polatuzumab vedotin.

研究的目的:

审查已批准的ADC在白血病和淋巴瘤的治疗疗效.
突出特定的ADC在各种血液性恶性瘤中的临床应用和结果.
确定对ADC耐药性机制进行进一步研究的需要.

主要方法:

在日本批准的抗体药物联合体 (ADCs) 对血液性恶性瘤的审查.
对gemtuzumab ozogamicin,brentuximab vedotin,inotuzumab ozogamicin和polatuzumab vedotin的临床试验数据的分析.
检查治疗结果,包括无进展生存率和完全缓解率.

主要成果:

吉姆图祖马布臭加米辛 (GO) 已被批准用于复发性/耐药性急性髓性白血病.
布伦图西马布维多丁 (BV) 在霍奇金淋巴瘤和外围T细胞淋巴瘤中证明了长时间的无进展生存期 (PFS).
在B细胞急性淋巴细胞白血病中,inotuzumab ozogamicin (IO) 显示出更高的完全缓解率,而在扩散大的B细胞淋巴瘤中,polatuzumab vedotin (PV) 组合治疗延长了PFS.

结论:

ADCs在治疗白血病和淋巴瘤方面表现出显著的治疗疗效.
与特定血液癌症的标准护理相比,已建立的ADC提供了更好的治疗选择.
了解和克服ADC耐药机制对于推进未来的癌症疗法至关重要.

更多相关视频

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...